Loading…
← CockpitCompetitor Analysis › CRON.TO Cronos Group IncOpen in the cockpit ↗

Cronos Group IncCRON.TOCompetitor analysis, valuation and peers

Canada · CAD·Health Care›Pharmaceuticals: Other

Produces and sells cannabis products in Canada and internationally under brands like Spinach and PEACE NATURALS.

Momentum leader 81
Mkt cap
$1.17B
US dollars, full cap
Free float
49%
of shares outstanding
$/day
$646,299
20-day average traded
Fwd P/E
16.2×
forward earnings
ROIC−WACC
-8.5 pp
WACC 10.2%
Hurdle
-8 pp
Req g minus delivered
Next earnings
106 days
4 Mar 2027
Close · CADC$4.57
1D-0.7%
1W-7.3%
1M-1.3%
3M+0.9%
6M+23.9%
YTD+26.9%
1Y+34.4%
ATR %3.7%
52w lowhigh16.4% off high

What Cronos does

Produces and sells cannabis products in Canada and internationally under brands like Spinach and PEACE NATURALS.

Canadian sales go to provincial wholesalers, which supply licensed shops, so the company sets wholesale prices but not shelf prices. Medical cannabis is exported to markets such as Israel and Germany. Altria, the tobacco company, is the largest shareholder; this Toronto line trades the same company as the US-listed shares.

Products and services

  • Spinach recreational cannabis
  • PEACE NATURALS medical cannabis
  • International medical cannabis (Israel, Germany)

Customers

  • Provincial cannabis retailers/distributors (Canada
  • Medical cannabis patients (international)

Where it sits in the supply chain

  • Cannabis
  • Cultivation & processing
  • Branded recreational/medical cannabis

What could go right

  • Altria's large equity stake and warrants
  • Potential US cannabis legalization optionality

What could go wrong

  • Oversupply/price compression in Canadian cannabis
  • Continued cash burn

Moat: none (brand). Recognizable recreational brand in a commoditized, oversupplied Canadian cannabis market.

Headquarters: Toronto, Canada · Employees: 610

Named competitors

  • Canopy Growth WEED.TO
  • Tilray TLRY.TO
  • Aurora Cannabis ACB.TO
  • Village Farms VFF

Cronos at a glance

Size Cronos (CRON.TO) is a Canada Health Care company (Pharmaceuticals: Other) with a market value of $1.17B, the 219th largest of 405 Canada companies the cockpit tracks. Shares closed at C$4.57 on 18 Nov 2026.

Performance Over six months the shares gained 23.9%, against -13.9% for the median peer and +1.1% for the Canada market (cap-weighted) — 5th highest of 21 in its peer set.

Growth Revenue grew 54.7% over the last twelve months (peer median +4.6%); the operating margin is 4.9% (peer median 14.4%).

Valuation It trades at 16.2× forward earnings against a peer median of 18.4× (8th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +27%, so the hurdle is -8 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 8.5 points below its cost of capital (10.2% WACC).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026CRON.TO 121Peer median 87
Six months, rebased to 100: Cronos against the median of its 20 peers (local-currency closes).

Cronos financials

Reported figures in CAD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueC$286MC$205MC$161MC$118MC$113M
Revenue growth—+27%+37%+4%—
Gross profitC$131MC$84.7MC$29.5MC$9.27MC$12.3M
EBITDAC$35.4M-C$4.61M-C$67.4M-C$97.2M-C$119M
Net incomeC$80.1M-C$13.2MC$56.3M-C$99.7M-C$219M
Free cash flowC$90.7MC$208,200C$8.81M-C$59.0M-C$120M
Capital expenditureC$22.1MC$36.4MC$18.0MC$4.62MC$6.55M
Total debtC$1.72MC$2.07MC$2.90MC$3.37MC$5.25M

Quarterly statements and history in the cockpit →

Cronos competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%PHM2142BIOG-B6472002275JWEL0719APN002219SUDEEPPHRMPHN60021604606032623003632877300791600488CRON.TO6-month return →1-month return →
Up and to the right = strong over both horizons. Cronos is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×100×PHM2142BIOG-B6472002275JWEL0719APN002219SUDEEPPHRM04606032622877300791CRON.TORevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Cronos is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%PHM2142BIOG-B6472002275JWEL0719APNPHN600216603262300791600056600488CRON.TOGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Cronos is the large dot.

Cronos competitors and peer comparison

Head to head with its named competitors (CRON.TO vs WEED.TO vs TLRY.TO vs ACB.TO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Cronos CRON.TO$1.17B+24%+55%5%16.2×18.8%
Canopy Growth WEED.TOn/a-50%n/an/an/an/a
Tilray Brands TLRY.TO$333M-56%+17%-6%n/an/a
Aurora Cannabis ACB.TOn/a+32%n/an/an/an/a
Village Farms International VFFn/a-16%n/an/an/an/a

How Cronos compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Cronos against its 20 peers (data as of 18 Nov 2026)
MeasureCRON.TOPeer medianRank in peer set
1-month return-1.3%-3.7%9th highest of 21
6-month return+23.9%-13.9%5th highest of 21
Distance from 52-week high-16.4%-34.6%6th highest of 21
Revenue growth (TTM)+54.7%+4.6%2nd highest of 21
Operating margin4.9%14.4%6th lowest of 21
Forward P/E16.2×18.4×8th cheapest of 17
Growth the price implies (Req g, 7 yrs)18.8%2.8%3rd most demanding of 17
Growth delivered (Del g)+26.7%+11.9%4th highest of 17
Hurdle (Req g minus delivered)-8.0 pp-10.5 pp7th most demanding of 17
ROIC minus cost of capital-8.5 pp+2.7 pplowest of 21
EV / EBITDA19.6×17.4×4th most expensive of 10
Net debt / EBITDA-29.8×-0.7×least indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Cronos CRON.TOCanada$1.17B+24%+55%5%16.2×18.8%+26.7%
Pharma Mar PHM.MCSpain$1.21B-38%+32%19%41.4×10.6%-3.9%
HBM 2142.HKHong Kong$1.12B-18%+55%44%11.7×13.1%+62.3%
BioGaia BIOG-B.STSweden$1.25B-4%+13%28%31.0×1.5%+15.5%
Bora Pharmaceuticals 6472.TWTaiwan$1.25B-2%+7%14%10.8×3.5%+60.2%
Guilin Sanjin Pharmaceutical 002275.SZChina$1.05B-12%-3%24%12.8×-8.7%+5.5%
Jamieson Wellness JWEL.TOCanada$1.32B+32%+12%13%20.6×13.5%+15.3%
Shandong Xinhua Pharmaceutical 0719.HKHong Kong$1.03B-19%-1%4%6.2×-2.1%+7.1%
Applied Nutrition APN.LUnited Kingdom$986M+31%+51%25%21.4×24.6%+38.5%
New Journey Health Technology Group Co., Ltd.Class A 002219.SZChina$942M-18%-14%8%182.0×n/an/a
Sudeep Pharma SUDEEPPHRM.NSIndia$1.45B+85%+27%33%69.1×n/an/a
PharmaNutra PHN.MIItaly$922M+2%+17%22%33.5×4.7%+18.5%
Zhejiang Medicine 600216.SSChina$1.51B-26%-6%7%11.5×-7.8%+3.9%
Tibet Cheezheng Tibetan Medicine 002287.SZChina$1.58B-17%-7%28%n/a-1.9%+10.4%
Sihuan Pharmaceutical 0460.HKHong Kong$856M-34%+30%15%8.7×n/an/a
TSI 603262.SSChina$842M-46%+3%14%47.7×24.3%+13.4%
Porton Pharma Solutions 300363.SZChina$1.66B+37%+6%-2%n/a2.1%+10.4%
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%7.6×n/an/a
Sirio Pharma 300791.SZChina$759M-6%-9%1%16.2×14.1%+15.6%
China Meheco 600056.SSChina$1.90B-16%+2%3%n/a-1.3%-2.1%
Tianjin Tianyao Pharmaceuticals 600488.SSChina$718M-36%-12%3%n/a2.1%-1.3%

Questions

Who are Cronos's main competitors?
Named competitors: Canopy Growth (WEED.TO), Tilray (TLRY.TO), Aurora Cannabis (ACB.TO), Village Farms (VFF). The cockpit's measured peer set (industry) also includes Pharma Mar (PHM.MC), HBM (2142.HK), BioGaia (BIOG-B.ST), Bora Pharmaceuticals (6472.TW), Guilin Sanjin Pharmaceutical (002275.SZ), Jamieson Wellness (JWEL.TO).
Is Cronos expensive compared with its peers?
On forward p/e it trades at 16.2× against a peer median of 18.4×, 8th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +27%, so the hurdle is -8 pp: the price already allows for a slowdown.
How has Cronos stock performed?
Over six months to 18 Nov 2026 the shares returned +23.9% against -13.9% for the median peer; over one year +34.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.